Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

Cancer is a multifactorial disease that affects millions of individuals worldwide and has a profound impact on public health. The heterogeneity of solid ...

A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

Keegan Paradis grew up watching his father, Brendon, lose his vision to a condition no one could name. "My wife said, 'Take ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...